Global HIV mortality trends among children on antiretroviral treatment corrected for under-reported deaths: an updated analysis of the International epidemiology Databases to Evaluate AIDS collaboration.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
09 2021
Historique:
received: 11 02 2021
accepted: 14 07 2021
entrez: 21 9 2021
pubmed: 22 9 2021
medline: 30 10 2021
Statut: ppublish

Résumé

The Joint United Nations Programme on HIV/AIDS (UNAIDS) projections of paediatric HIV prevalence and deaths rely on the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium for mortality estimates among children living with HIV (CHIV) receiving antiretroviral therapy (ART). Previous estimates, based on data through 2014, may no longer be accurate due to expanded paediatric HIV care and treatment eligibility, and the possibility of unreported deaths in CHIV considered lost to follow-up (LTFU). We therefore estimated all-cause mortality and its trends in CHIV (<15 years old) on ART using extended and new IeDEA data. We analysed (i) IeDEA observational data from CHIV in routine care globally, and (ii) novel data from an IeDEA tracing study that determined outcomes in a sample of CHIV after being LTFU in southern Africa. We included 45,711 CHIV on ART during 2004 to 2017 at 72 programmes in Africa, Asia-Pacific and Latin America. We used mixed effects Poisson regression to estimate mortality by age, sex, CD4 at ART start, time on ART, region and calendar year. For Africa, in an adjusted analysis that accounts for unreported deaths among those LTFU, we first modified the routine data by simulating mortality outcomes within six months after LTFU, based on a Gompertz survival model fitted to the tracing data (n = 221). Observed mortality rates were 1.8 (95% CI: 1.7 to 1.9) and 9.4 (6.3 to 13.4) deaths per 100 person-years in the routine and tracing data, respectively. We found strong evidence of higher mortality at shorter ART durations, lower CD4 values, and in infancy. Averaging over covariate patterns, the adjusted mortality rate was 54% higher than the unadjusted rate. In unadjusted analyses, mortality reduced by an average 60% and 73% from 2005 to 2017, within and outside of Africa, respectively. In the adjusted analysis for Africa, this temporal reduction was 42%. Mortality rates among CHIV have decreased substantially over time. However, when accounting for worse outcomes among those LTFU, mortality estimates increased and temporal improvements were slightly reduced, suggesting caution in interpreting analyses based only on programme data. The improved and updated IeDEA estimates on mortality among CHIV on ART support UNAIDS efforts to accurately model global HIV statistics.

Identifiants

pubmed: 34546646
doi: 10.1002/jia2.25780
pmc: PMC8454681
doi:

Substances chimiques

Anti-HIV Agents 0
Anti-Retroviral Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25780

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI096299
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069911
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069919
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069907
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069924
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069923
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI124872
Pays : United States

Informations de copyright

© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

Pediatrics. 2011 Feb;127(2):e423-41
pubmed: 21262891
AIDS. 2019 Dec 15;33 Suppl 3:S227-S234
pubmed: 31805028
J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):208-19
pubmed: 23187940
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 1:S22-S26
pubmed: 29994916
PLoS Med. 2007 Oct 16;4(10):e298
pubmed: 17941716
Curr Opin HIV AIDS. 2016 Sep;11(5):455-464
pubmed: 27716730
BMC Res Notes. 2020 May 24;13(1):249
pubmed: 32448379
PLoS One. 2009 Jun 04;4(6):e5790
pubmed: 19495419
Stat Med. 2014 Jan 15;33(1):129-42
pubmed: 23873614
J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):e40-6
pubmed: 21407085
Clin Infect Dis. 2021 May 16;:
pubmed: 33993219
Clin Infect Dis. 2018 Nov 13;67(11):1643-1652
pubmed: 29889240
J Int AIDS Soc. 2020 Jun;23 Suppl 2:e25530
pubmed: 32589367
AIDS. 2019 Dec 15;33 Suppl 3:S283-S294
pubmed: 31800405
BMJ Open. 2020 May 15;10(5):e035246
pubmed: 32414825
PLoS Med. 2018 Mar 1;15(3):e1002514
pubmed: 29494593
Lancet HIV. 2015 Mar;2(3):e107-16
pubmed: 26424542
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
Pediatr Infect Dis J. 2020 Feb;39(2):127-133
pubmed: 31725119
J Int AIDS Soc. 2020 Jun;23 Suppl 2:e25510
pubmed: 32589347
Int J Epidemiol. 2012 Oct;41(5):1256-64
pubmed: 21593078
AIDS. 2017 Apr;31 Suppl 1:S13-S22
pubmed: 28301337
Int J Epidemiol. 2007 Oct;36(5):969-76
pubmed: 17846055
AIDS. 2019 Dec 1;33(15):2375-2386
pubmed: 31764102

Auteurs

Reshma Kassanjee (R)

Centre for Infectious Disease Epidemiology and Research (CIDER), School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Leigh F Johnson (LF)

Centre for Infectious Disease Epidemiology and Research (CIDER), School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Elizabeth Zaniewski (E)

Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.

Marie Ballif (M)

Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.

Benedikt Christ (B)

Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.

Constantin T Yiannoutsos (CT)

Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, USA.

Patience Nyakato (P)

Centre for Infectious Disease Epidemiology and Research (CIDER), School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Sophie Desmonde (S)

Centre d'Epidémiologie et de Recherche en santé des Populations (CERPOP), Inserm U1027/University Toulouse 3, Toulouse, France.

Andrew Edmonds (A)

Department of Epidemiology, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Tavitiya Sudjaritruk (T)

Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Clinical and Molecular Epidemiology of Emerging and Re-emerging Infectious Diseases Research Cluster, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Jorge Pinto (J)

School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.

Rachel Vreeman (R)

Department of Global Health and Health System Design, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Arnhold Institute for Global Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.

Désiré Lucien Dahourou (DL)

Centre d'Epidémiologie et de Recherche en santé des Populations (CERPOP), Inserm U1027/University Toulouse 3, Toulouse, France.
Département Biomédical/Santé Publique, Institut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso.

Christelle Twizere (C)

CA-IeDEA Burundi, Centre National de Référence en matière de VIH/SIDA (CNR), Bujumbura, Burundi.

Azar Kariminia (A)

Kirby Institute, UNSW Sydney, Sydney, Australia.

James G Carlucci (JG)

Ryan White Center for Pediatric Infectious Diseases and Global Health, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Charles Kasozi (C)

Masaka Regional Referral Hospital, Masaka, Uganda.

Mary-Ann Davies (MA)

Centre for Infectious Disease Epidemiology and Research (CIDER), School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH